<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/51B3600A-54C2-4F6B-99AE-03CD7220EBBA"><gtr:id>51B3600A-54C2-4F6B-99AE-03CD7220EBBA</gtr:id><gtr:name>Royal College of Surgeons in Ireland</gtr:name><gtr:address><gtr:line1>Academic Centre</gtr:line1><gtr:line2>Coombe Women's Hospital</gtr:line2><gtr:line3>Dublin 8</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>Ireland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F75103EE-8294-429F-BC9F-70CBED7DA893"><gtr:id>F75103EE-8294-429F-BC9F-70CBED7DA893</gtr:id><gtr:name>St Jude Children's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FCD90BB9-BD1C-43D4-98EE-AE74283911E3"><gtr:id>FCD90BB9-BD1C-43D4-98EE-AE74283911E3</gtr:id><gtr:name>Free University of Brussels (ULB)</gtr:name><gtr:address><gtr:line1>Avenue Franklin Roosevelt 50</gtr:line1><gtr:postCode>B-1050</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7A2E29F2-7BB5-49F8-A719-BCDDF0C000FA"><gtr:id>7A2E29F2-7BB5-49F8-A719-BCDDF0C000FA</gtr:id><gtr:name>University of Otago</gtr:name><gtr:address><gtr:line1>PO Box 56</gtr:line1><gtr:line4>Dunedin</gtr:line4><gtr:line5>9016</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>New Zealand</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/51B3600A-54C2-4F6B-99AE-03CD7220EBBA"><gtr:id>51B3600A-54C2-4F6B-99AE-03CD7220EBBA</gtr:id><gtr:name>Royal College of Surgeons in Ireland</gtr:name><gtr:address><gtr:line1>Academic Centre</gtr:line1><gtr:line2>Coombe Women's Hospital</gtr:line2><gtr:line3>Dublin 8</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>Ireland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F75103EE-8294-429F-BC9F-70CBED7DA893"><gtr:id>F75103EE-8294-429F-BC9F-70CBED7DA893</gtr:id><gtr:name>St Jude Children's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FCD90BB9-BD1C-43D4-98EE-AE74283911E3"><gtr:id>FCD90BB9-BD1C-43D4-98EE-AE74283911E3</gtr:id><gtr:name>Free University of Brussels (ULB)</gtr:name><gtr:address><gtr:line1>Avenue Franklin Roosevelt 50</gtr:line1><gtr:postCode>B-1050</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7A2E29F2-7BB5-49F8-A719-BCDDF0C000FA"><gtr:id>7A2E29F2-7BB5-49F8-A719-BCDDF0C000FA</gtr:id><gtr:name>University of Otago</gtr:name><gtr:address><gtr:line1>PO Box 56</gtr:line1><gtr:line4>Dunedin</gtr:line4><gtr:line5>9016</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>New Zealand</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/414D6059-7ED1-4FAE-986D-FFE89883FFC2"><gtr:id>414D6059-7ED1-4FAE-986D-FFE89883FFC2</gtr:id><gtr:firstName>Sanjay</gtr:firstName><gtr:surname>Sisodiya</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B502872D-53F9-42EB-8D1E-45D7522C3D98"><gtr:id>B502872D-53F9-42EB-8D1E-45D7522C3D98</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Wood</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4E19D084-70D2-4EE0-99CC-087F4083DED0"><gtr:id>4E19D084-70D2-4EE0-99CC-087F4083DED0</gtr:id><gtr:firstName>L</gtr:firstName><gtr:surname>Sander</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3AF338C5-29C8-4764-96B5-61846F13F152"><gtr:id>3AF338C5-29C8-4764-96B5-61846F13F152</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Goldstein</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400126"><gtr:id>2249D45D-DD14-43A1-9CD9-0514218E9160</gtr:id><gtr:title>Population genetic studies of susceptibility and treatment response in epilepsy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400126</gtr:grantReference><gtr:abstractText>Epilepsy is an important condition, affecting 300,000 people in the UK alone. It increases the chances of early death, and is associated with psychological, social and financial disadvantages. The annual cost to the UK economy is over #500 million/year in direct costs alone, and much of this cost is due to epilepsy that is poorly controlled. Despite extensive research, we still know little about the causes of epilepsy and the causes of variable response to conventional antiepileptic drug treatment. Studies of rare families where multiple members are affected by epilepsy has revealed that mutations in specific genes (eg SCN1A, SCN1B, GABRG2) can cause some rare types of epilepsy. We have shown that common variation (polymorphism) in one (SCN1A ) of these genes (rather than rare mutation in that gene) also influences susceptibility to epilepsy in a large number of patients with epilepsy in whom there was not a clear inherited pattern of epilepsy. We have also shown that variation in another particular gene can influence to some degree how individuals patients might respond to antiepileptic drugs. These important findings show how common genetic variation, rather than rare genetic mutations, might have an effect on the risk of developing epilepsy and the response to antiepileptic drugs. Spurred on by these findings and the rapid advance in genetic knowledge and technology, we wish to study a larger range of carefully-selected genes in a large group of individuals with well-characterised epilepsy to identify other common variants that may have an important impact on susceptibility to and drug response in epilepsy. Once such genetic variants have been found, further detailed experiments can be devised to determine which variants are actually important at a clinical level and how such variants might exert their effects. Eventually, the resulting knowledge may lead to better treatment options, treatment tailored to the individual?s make-up, and perhaps even ways in which epilepsy might actually be prevented. 
All the results from this project will be disseminated to the medical and scientific communities, related professionals and the lay public through the scientific media, conferences, press releases and patient support bodies, such as through the Department of Information and Education at the National Society for Epilepsy, an integral part of the working practices of the applicants.</gtr:abstractText><gtr:technicalSummary>Epilepsy is an important condition: it affects 300,000 people in the UK, is associated with increased mortality and morbidity for patients, and costs the UK over #500 million/year. Significant problems plague epilepsy management: drug treatment is ineffective in 30% of patients, and an understanding of disease susceptibility is lacking, making prevention impossible. Heterogeneity in aspects of epilepsy suggests common genetic variation may contribute to disease susceptibility and treatment response. In large cohort studies, we showed genetic susceptibility to resistance to drug treatment (gene: ABCB1) and susceptibility to epilepsy with a history of febrile seizures (gene: SCN1A). The objectives of the proposed research are: (1) to identify genetic variants associated with susceptibility to, and drug response in, epilepsy using haplotype mapping on a large set of selected candidate genes; (2) to undertake directed genetic and clinical follow-up of our previous findings in one paradigmatic gene (SCN1A), and similar follow-up for other associations detected in this project. Large patient resources will be marshalled (we already have ~1,200 DNA samples): detailed phenotypic data will be collected for all patients on a bespoke interrogable secure database. Candidate genes will be carefully selected based on data from Mendelian epilepsies and pathophysiological considerations. Haplotype mapping (using HapMap, industrial collaborators and resequencing gene data) for these selected genes, will be undertaken in 2,000 well-characterised patients with epilepsy and 2,000 controls on a Taqman platform supported by the cooperative core. Statistical methods for choice of tagging single nucleotide polymorphisms and population genetic analyses will be applied, and genomic control for stratification (as in our ABCB1 work) will be employed. Gene interactions will be investigated. We will attempt to replicate identified associations in a second independent patient cohort. The general paradigm has already been undertaken for SCN1A in epilepsy and has identified an association between certain tagging SNPs and epilepsy with a history of febrile seizures. In this proposal, we will also follow these findings up for SCN1A, with directed genetic work to identify candidate causal variants, and clinical work to identify the time of action of such variants in the natural history of epilepsy and febrile seizures. Our SCN1A results show that genetic susceptibility can cut across current classifications, and could potentially identify at an early stage genetically at-risk individuals in whom targeted intervention could lead to prevention of the development of epilepsy. This is the long-term potential of the proposed research, to improve treatment and facilitate prevention.</gtr:technicalSummary><gtr:fund><gtr:end>2009-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>473539</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Otago</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:department>Department of Medicine</gtr:department><gtr:description>SCN1A replication study</gtr:description><gtr:id>D50C586D-1787-4D5E-A80F-71C2B3C9C2F9</gtr:id><gtr:impact>Manuscript: 19949041</gtr:impact><gtr:outcomeId>C1250C8A040-1</gtr:outcomeId><gtr:partnerContribution>Additional cases</gtr:partnerContribution><gtr:piContribution>Data provision, intellectual input</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UCB Pharma</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Levetiracetam pharmacogenomics</gtr:description><gtr:id>8EE20849-6B5C-4B92-B60A-2237F97EDC81</gtr:id><gtr:impact>Publication and further grant support for levetiracetam genome-wide pharmacogenomics Output: 18977120</gtr:impact><gtr:outcomeId>4A8B77884F1-1</gtr:outcomeId><gtr:piContribution>Acquired and processed data</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Jude Children's Hospital</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>CYP2C9 studies</gtr:description><gtr:id>550142FA-D47A-4864-BBEB-1595B169C1A2</gtr:id><gtr:impact>Resulting manuscript : 19855097</gtr:impact><gtr:outcomeId>2472590552D-1</gtr:outcomeId><gtr:partnerContribution>Scientific input, intellectual input, study coordination</gtr:partnerContribution><gtr:piContribution>Case data and clinical interpretation</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal College of Surgeons in Ireland</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>EPIGEN</gtr:description><gtr:id>1F8014E2-03AE-4639-B7FB-CA23C8A326B0</gtr:id><gtr:impact>Several manuscripts as detailed in first section</gtr:impact><gtr:outcomeId>8090F7AAE47-1</gtr:outcomeId><gtr:partnerContribution>Additional cases and intellectual inputadditional cases and intellectual inputAdditional cases, intellectual input and genotyping</gtr:partnerContribution><gtr:piContribution>Contribution to leadership, research strategy, further funding and publications</gtr:piContribution><gtr:sector>Learned Society</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Free University of Brussels</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>EPIGEN</gtr:description><gtr:id>985F322F-1714-4AC9-AEDC-7B793B3DACBA</gtr:id><gtr:impact>Several manuscripts as detailed in first section</gtr:impact><gtr:outcomeId>8090F7AAE47-2</gtr:outcomeId><gtr:partnerContribution>Additional cases and intellectual inputadditional cases and intellectual inputAdditional cases, intellectual input and genotyping</gtr:partnerContribution><gtr:piContribution>Contribution to leadership, research strategy, further funding and publications</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Duke University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>EPIGEN</gtr:description><gtr:id>5333D094-40B4-430A-977D-2FFBF99296FD</gtr:id><gtr:impact>Several manuscripts as detailed in first section</gtr:impact><gtr:outcomeId>8090F7AAE47-3</gtr:outcomeId><gtr:partnerContribution>Additional cases and intellectual inputadditional cases and intellectual inputAdditional cases, intellectual input and genotyping</gtr:partnerContribution><gtr:piContribution>Contribution to leadership, research strategy, further funding and publications</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>magazine/periodical</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>3B6AE964-F9E3-4996-9D86-E701069595C0</gtr:id><gtr:impact>Description of research and potential

Interest, new recruits, minor funding</gtr:impact><gtr:outcomeId>7515BFE9476</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AGMs of epilepsy charities</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>697BC1D3-E8F2-432E-AF38-5F3FF62678FE</gtr:id><gtr:impact>Description of research activity and outcome and potential to patients and carers

Minor fundraising</gtr:impact><gtr:outcomeId>9D87C70906B</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>SUDEP research</gtr:description><gtr:end>2014-07-02</gtr:end><gtr:fundingOrg>CURE Epilepsy</gtr:fundingOrg><gtr:id>7E79AF06-2CB7-46C3-AFE8-B23882752BD9</gtr:id><gtr:outcomeId>fH1BEwuHXT7</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Strategic Award</gtr:description><gtr:end>2020-03-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>CCBD757D-F9AB-4F40-84AA-EB3F09A17DE3</gtr:id><gtr:outcomeId>54611f24848cd5.26097278</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1375000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Genomics of Common Diseases (Genome-wide association studies in partial epilepsies)</gtr:description><gtr:end>2014-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>1FF67EBB-38B1-4B0A-9163-9406E8062EB4</gtr:id><gtr:outcomeId>8EDB0FBFF5D0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Web-based database for data collection for population genetic studies in epilepsy DNA resource</gtr:description><gtr:id>9D1B4A82-E7AF-47D6-AA9F-5F50DCDA8B8F</gtr:id><gtr:impact>facilitation of multicentre studies</gtr:impact><gtr:outcomeId>6775223F7FD</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>DNA resource and clinical database</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>03EC2C48-901B-4D47-B429-3502EA84FB9D</gtr:id><gtr:title>Genetics of epilepsy: epilepsy research foundation workshop report.</gtr:title><gtr:parentPublicationTitle>Epileptic disorders : international epilepsy journal with videotape</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c68df3b2ba4827cafde3a4c6b3cf0167"><gtr:id>c68df3b2ba4827cafde3a4c6b3cf0167</gtr:id><gtr:otherNames>Sisodiya S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1294-9361</gtr:issn><gtr:outcomeId>5a5c92b9d9b2c4.80679453</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE29C91D-0C4E-4D54-A068-BC4F2ABFA3CB</gtr:id><gtr:title>Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions.</gtr:title><gtr:parentPublicationTitle>Pharmacogenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e93a8be14f67f13f871370dbb8d62e3"><gtr:id>7e93a8be14f67f13f871370dbb8d62e3</gtr:id><gtr:otherNames>McCormack M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1462-2416</gtr:issn><gtr:outcomeId>pm_13860_20_22379998</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D1898F7-2C29-4697-B5F5-9BC80E41DFEC</gtr:id><gtr:title>Alternative ion channel splicing in mesial temporal lobe epilepsy and Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Genome biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5cc40dfc64d4f648f783ef445045a4ff"><gtr:id>5cc40dfc64d4f648f783ef445045a4ff</gtr:id><gtr:otherNames>Heinzen EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1474-7596</gtr:issn><gtr:outcomeId>C9A199F6E83</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F0CE099-A815-436F-91C1-461F31BF6922</gtr:id><gtr:title>Genetics of antiepileptic drug resistance.</gtr:title><gtr:parentPublicationTitle>Current opinion in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/720f44ce167f75a03764bbcbbeb1ee3d"><gtr:id>720f44ce167f75a03764bbcbbeb1ee3d</gtr:id><gtr:otherNames>Sisodiya SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1350-7540</gtr:issn><gtr:outcomeId>pm_13860_10_19532038</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5180FB3-702E-48C9-8ACE-A6059E36C32E</gtr:id><gtr:title>CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.</gtr:title><gtr:parentPublicationTitle>The Journal of pharmacology and experimental therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1eec9ba70abdb4f227eb9e750c0e5e2"><gtr:id>b1eec9ba70abdb4f227eb9e750c0e5e2</gtr:id><gtr:otherNames>Chaudhry AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-3565</gtr:issn><gtr:outcomeId>B335FDF5A9D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9145CD78-EEED-467F-BF7D-1CB6734A4818</gtr:id><gtr:title>Common genetic variation and susceptibility to partial epilepsies: a genome-wide association study.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1bc530dea0f047a0508cb343a8ec2de"><gtr:id>c1bc530dea0f047a0508cb343a8ec2de</gtr:id><gtr:otherNames>Kasperaviciute D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>6E32B8D6894</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1F88E4B-B00D-4FEE-A219-A68D28AB394C</gtr:id><gtr:title>No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.</gtr:title><gtr:parentPublicationTitle>Epilepsy research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39b64d3ef3b2a06841d419dc7fa8db61"><gtr:id>39b64d3ef3b2a06841d419dc7fa8db61</gtr:id><gtr:otherNames>Lynch JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0920-1211</gtr:issn><gtr:outcomeId>A25F53180A8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1916D51-8E0B-46C5-A1E4-74418C991BEA</gtr:id><gtr:title>Uncovering genomic causes of co-morbidity in epilepsy: gene-driven phenotypic characterization of rare microdeletions.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1bc530dea0f047a0508cb343a8ec2de"><gtr:id>c1bc530dea0f047a0508cb343a8ec2de</gtr:id><gtr:otherNames>Kasperaviciute D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>jejQEPxBeYE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F1472DB-D5F4-41D7-8CBD-615C83869664</gtr:id><gtr:title>Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5cc40dfc64d4f648f783ef445045a4ff"><gtr:id>5cc40dfc64d4f648f783ef445045a4ff</gtr:id><gtr:otherNames>Heinzen EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>cPfroJri4tP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA958C98-93FC-4028-830E-B5319ABB6D46</gtr:id><gtr:title>HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e93a8be14f67f13f871370dbb8d62e3"><gtr:id>7e93a8be14f67f13f871370dbb8d62e3</gtr:id><gtr:otherNames>McCormack M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>DNESH5cV6c7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>432FC9BC-87F8-42E4-93EE-7A2F2C772EF4</gtr:id><gtr:title>Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0aabcf3318f5a7b593a0ea7608a3439b"><gtr:id>0aabcf3318f5a7b593a0ea7608a3439b</gtr:id><gtr:otherNames>Postmus I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5a5c92a74ca8f4.40096352</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AF62FBD-7EA3-4CD0-95BF-39808B7153E1</gtr:id><gtr:title>Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7204e0994584ae87d35d658678945308"><gtr:id>7204e0994584ae87d35d658678945308</gtr:id><gtr:otherNames>Cavalleri GL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>EE7CF66278F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97D69947-973B-4642-976E-4F4707801A4F</gtr:id><gtr:title>Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control study</gtr:title><gtr:parentPublicationTitle>LANCET NEUROLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b83e47c95c5c571c5fd5e8695e883b3e"><gtr:id>b83e47c95c5c571c5fd5e8695e883b3e</gtr:id><gtr:otherNames>CAVALLERI, GL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>5a5c92ba43e2d6.82999667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABE369BD-52AB-48B3-BD97-349DA0614BB4</gtr:id><gtr:title>Genomic microdeletions associated with epilepsy: not a contraindication to resective surgery.</gtr:title><gtr:parentPublicationTitle>Epilepsia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a00589077243b34788cc702c9437ae2c"><gtr:id>a00589077243b34788cc702c9437ae2c</gtr:id><gtr:otherNames>Catarino CB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0013-9580</gtr:issn><gtr:outcomeId>jkJZL2ppXct</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C021E49-1450-48DC-ABCC-401F8432469A</gtr:id><gtr:title>Genome-wide association analysis identifies 13 new risk loci for schizophrenia.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c8d6984e5c8a907d8380f687ccba0dd"><gtr:id>9c8d6984e5c8a907d8380f687ccba0dd</gtr:id><gtr:otherNames>Ripke S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>5a5c92a8a034a8.05033576</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8C05A48-E6FA-4BF6-8440-08E37872A2A9</gtr:id><gtr:title>Lack of support for a role for RLIP76 (RALBP1) in response to treatment or predisposition to epilepsy.</gtr:title><gtr:parentPublicationTitle>Epilepsia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ffd6dd8cdc7abeddb6d54b25243f8af"><gtr:id>6ffd6dd8cdc7abeddb6d54b25243f8af</gtr:id><gtr:otherNames>Soranzo N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0013-9580</gtr:issn><gtr:outcomeId>B4CC3B0A3D2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8621F317-FE40-42EC-A78E-FFCEC70C08D2</gtr:id><gtr:title>Genome-wide association study of intraocular pressure identifies the GLCCI1/ICA1 region as a glaucoma susceptibility locus.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73959b4dfbf87ceb414beec488b20336"><gtr:id>73959b4dfbf87ceb414beec488b20336</gtr:id><gtr:otherNames>Blue Mountains Eye Study (BMES)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>5a5c92a8bb2fa4.64777289</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA379740-DABD-40ED-B6BB-82E11FFDED75</gtr:id><gtr:title>Lack of replication of association between scn1a SNP and febrile seizures.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4633cc5115042b7d5befd3c4cfa05c5b"><gtr:id>4633cc5115042b7d5befd3c4cfa05c5b</gtr:id><gtr:otherNames>Petrovski S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>9B12312F2AB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30E33E49-7C2F-4517-B50C-3BCBB77B6D92</gtr:id><gtr:title>Neuropathology of 16p13.11 deletion in epilepsy.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13f3704d16a7d01e3af5f5c48b42b928"><gtr:id>13f3704d16a7d01e3af5f5c48b42b928</gtr:id><gtr:otherNames>Liu JY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13860_20_22523559</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98B1AF44-4257-45FF-8D4B-8EF313286AA3</gtr:id><gtr:title>A multicenter study of BRD2 as a risk factor for juvenile myoclonic epilepsy.</gtr:title><gtr:parentPublicationTitle>Epilepsia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7204e0994584ae87d35d658678945308"><gtr:id>7204e0994584ae87d35d658678945308</gtr:id><gtr:otherNames>Cavalleri GL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0013-9580</gtr:issn><gtr:outcomeId>9DE65DCEB02</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71BFA97A-1090-4F91-8BE7-BF05428BD68F</gtr:id><gtr:title>Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5cc40dfc64d4f648f783ef445045a4ff"><gtr:id>5cc40dfc64d4f648f783ef445045a4ff</gtr:id><gtr:otherNames>Heinzen EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>BAF3FCE6425</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0EE5AFA-55AE-4C94-8525-4A1E86F8D489</gtr:id><gtr:title>Etiology and management of refractory epilepsies.</gtr:title><gtr:parentPublicationTitle>Nature clinical practice. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c68df3b2ba4827cafde3a4c6b3cf0167"><gtr:id>c68df3b2ba4827cafde3a4c6b3cf0167</gtr:id><gtr:otherNames>Sisodiya S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1745-834X</gtr:issn><gtr:outcomeId>D5C86E29CC5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7693027-7634-4F2C-A417-9AFC56558D29</gtr:id><gtr:title>An assessment of the Irish population for large-scale genetic mapping studies involving epilepsy and other complex diseases.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54d6f491a2b7de8ec215c956410e8a9c"><gtr:id>54d6f491a2b7de8ec215c956410e8a9c</gtr:id><gtr:otherNames>O'Dushlaine CT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>CFAA64A0B68</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EAB88546-92DD-4BFF-86EE-636CA664B4C9</gtr:id><gtr:title>Genetic contribution to common epilepsies.</gtr:title><gtr:parentPublicationTitle>Current opinion in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/720f44ce167f75a03764bbcbbeb1ee3d"><gtr:id>720f44ce167f75a03764bbcbbeb1ee3d</gtr:id><gtr:otherNames>Sisodiya SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1350-7540</gtr:issn><gtr:outcomeId>AHFGmkWC6B5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>118F5050-25D2-4165-AFF4-9631AC891D17</gtr:id><gtr:title>Meta-analysis of genome-wide association studies identifies novel loci that influence cupping and the glaucomatous process.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e25834a5f4a7ef0720986db65b2dc3dd"><gtr:id>e25834a5f4a7ef0720986db65b2dc3dd</gtr:id><gtr:otherNames>Springelkamp H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5a5c92a7050b20.13627503</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>191C804D-DEC9-49DD-8AE5-1935809AF11F</gtr:id><gtr:title>Epilepsy, hippocampal sclerosis and febrile seizures linked by common genetic variation around SCN1A.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1bc530dea0f047a0508cb343a8ec2de"><gtr:id>c1bc530dea0f047a0508cb343a8ec2de</gtr:id><gtr:otherNames>Kasperaviciute D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_13860_20_24014518</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABF60849-7A27-4B2A-895F-B4E77AE3E6C5</gtr:id><gtr:title>The correlation between reading and mathematics ability at age twelve has a substantial genetic component.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a21057783f3c05e437394738de1d27a"><gtr:id>6a21057783f3c05e437394738de1d27a</gtr:id><gtr:otherNames>Davis OS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5a5c92a7df3838.48480249</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CD98491-BBA2-4330-B042-A710EEA229CC</gtr:id><gtr:title>Characterisation and validation of insertions and deletions in 173 patient exomes.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e624c5192e4cb8e4e04042cdb89976af"><gtr:id>e624c5192e4cb8e4e04042cdb89976af</gtr:id><gtr:otherNames>Lescai F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13860_20_23251486</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400126</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>